Sagimet Biosciences Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SGMT Nasdaq 2836 www.sagimet.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sagimet Biosciences Inc.

Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - Jan 8th, 2026 5:00 am
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely - Dec 23rd, 2025 4:31 am
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination - Dec 18th, 2025 5:00 am
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program - Dec 17th, 2025 5:00 am
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration - Dec 10th, 2025 5:03 am
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 9th, 2025 2:05 pm
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference - Nov 20th, 2025 5:00 am
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - Nov 13th, 2025 5:30 am
While institutions own 29% of Sagimet Biosciences Inc. (NASDAQ:SGMT), individual investors are its largest shareholders with 45% ownership - Nov 11th, 2025 4:44 am
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025 - Nov 10th, 2025 5:00 am
Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference - Oct 24th, 2025 5:00 am
All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy - Oct 15th, 2025 10:00 am
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - Oct 14th, 2025 5:00 am
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025 - Oct 7th, 2025 5:00 am
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination - Oct 1st, 2025 5:00 am
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week - Sep 24th, 2025 5:00 am
Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis - Sep 17th, 2025 5:00 am
Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks - Sep 16th, 2025 7:35 am
Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit - Sep 10th, 2025 5:00 am
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences - Aug 26th, 2025 5:00 am